Unum
UNM
$86.45
-1.53%
Unum Group is a leading provider of group and individual income protection insurance, primarily offering disability, life, and long-term care insurance in the U.S., U.K., and Poland. As the largest domestic disability insurer, it generates most premiums from employer-sponsored plans, distinguishing it as a dominant player in the employee benefits space. The current investor narrative centers on Unum's ability to sustain premium growth, execute aggressive share buybacks, and stabilize margins amid a shifting interest rate environment and competitive pressures. Recent focus has been on management's capital deployment strategy and the trajectory of its core Unum USA segment.…
UNM
Unum
$86.45
Related headlines
Investment Opinion: Should I buy UNM Today?
Rating: Buy. Unum offers a compelling risk/reward with a forward P/E of 9.2x, strong revenue growth, and aggressive capital returns. The analyst consensus is Buy with an average target of $101.38, implying 13.8% upside.
Supporting evidence: (1) Forward P/E of 9.2x is a discount to the trailing P/E of 18.1x and the life insurance sector average of 10-15x. (2) Revenue grew 9.02% YoY in Q1 2026. (3) TTM free cash flow of $538.8M supports dividends and buybacks. (4) ROE of 6.64% is reasonable for an insurer. The stock appears undervalued on a forward basis relative to its own history and peers.
Risks: Margin compression could persist if claims costs rise. The trailing P/E premium could unwind if earnings growth stalls. This Buy would downgrade to Hold if operating margins fall below 8% or revenue growth decelerates below 5%. Overall, Unum is undervalued based on forward earnings and cash flow generation.
Sign up to view all
UNM 12-Month Price Forecast
Unum's forward valuation is attractive, and the company's strong cash generation supports capital returns. The primary risk is margin compression, but the base case of steady growth and buyback accretion should drive the stock toward the average target. The bullish stance is supported by the forward P/E discount and revenue momentum, but confidence is medium due to margin uncertainty. An upgrade to high confidence would require operating margins to stabilize above 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Unum's 12-month outlook, with a consensus price target around $102.23 and implied upside of +18.3% versus the current price.
Average Target
$102.23
0 analysts
Implied Upside
+18.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $123
Analyst target range
Unum is covered by 13 analysts, with a consensus recommendation of 'Buy' (mean rating 1.77 on a 1-5 scale, where 1 is Strong Buy). The average price target is $101.38, implying approximately 13.8% upside from the current price of $89.05. The distribution leans bullish, with no sell ratings and a majority of buy/outperform ratings. Recent ratings from Evercore ISI, Jefferies, Wells Fargo, and Barclays all reaffirm positive stances, indicating strong institutional conviction. The target range spans from $87.00 (low) to $123.00 (high), a spread of $36 or 41% of the average target, reflecting moderate uncertainty. The high target of $123 assumes significant multiple expansion or accelerated earnings growth, potentially driven by higher interest rates benefiting Unum's investment portfolio or better-than-expected underwriting margins. The low target of $87, slightly below the current price, suggests downside risk if premium growth stalls or claims costs rise. The tight clustering of recent ratings (all positive) and the narrow range between the low and current price indicate that analysts see limited downside but varied upside potential. The absence of downgrades in the past three months reinforces the bullish consensus.
Drowning in data?
Find the real signal!
Bulls vs Bears: UNM Investment Factors
Unum presents a mixed picture: strong revenue growth, aggressive buybacks, and a low forward P/E support the bull case, while margin compression, elevated trailing P/E, and limited analyst upside temper enthusiasm. The bull case currently has stronger evidence given the forward P/E discount and robust cash generation, but the key tension is whether margin stabilization will materialize. If operating margins recover to 12%+ levels, the stock could re-rate higher; if they continue to decline, the trailing P/E premium could unwind.
Bullish
- Strong Revenue Growth: Revenue grew 9.02% YoY in Q1 2026 to $3.355B, driven by the core Unum USA segment ($2.066B). This consistent expansion supports premium growth and market share retention.
- Aggressive Share Buybacks: Unum repurchased $398.8M in shares in Q1 2026 alone, reducing diluted shares from 178.9M to 164.4M YoY. This capital return program boosts EPS and signals management confidence.
- Attractive Forward Valuation: With a forward P/E of 9.2x, Unum trades at a discount to its trailing P/E of 18.1x and the life insurance sector average of 10-15x. This implies significant earnings growth is expected.
- Robust Free Cash Flow: TTM free cash flow of $538.8M provides ample coverage for dividends ($78.2M) and buybacks. The FCF yield of ~4.0% is healthy for an insurer.
Bearish
- Elevated Trailing P/E: The trailing P/E of 18.1x is near the top of its 5-year historical range (4x-19x), suggesting the stock is priced for optimistic expectations. Any earnings miss could trigger multiple compression.
- Margin Compression Risk: Operating margin fell from 12.46% in Q2 2025 to 9.02% in Q1 2026, while net margin declined from 10.03% to 6.91%. Rising costs or claims could further pressure profitability.
- Low Analyst Target Upside: The average analyst target of $101.38 implies only 13.8% upside, and the low target of $87 suggests potential downside from the current price of $89.05. Limited upside reduces the risk/reward appeal.
- Interest Rate Sensitivity: Unum's investment portfolio benefits from higher rates, but a rate-cutting cycle could compress net investment income. The company's debt-to-equity of 0.35 is manageable but exposes it to refinancing risk.
UNM Technical Analysis
Unum's 1-year price change of +9.92% reflects a sustained uptrend, with the stock currently trading at $89.05, approximately 95.5% of its 52-week range ($68.28–$93.22). This positioning near the upper end of the range suggests strong momentum and bullish sentiment, though it also raises caution about potential overextension. The stock's beta of 0.236 indicates significantly lower volatility than the broader market, making it a defensive holding within the financial services sector. Over the past 3 months, Unum has gained 11.83%, outperforming the S&P 500's 4.67% return, highlighting relative strength. However, the 1-month price change of -2.81% contrasts with the longer-term uptrend, signaling a short-term pullback. This divergence could represent a healthy consolidation or profit-taking after the strong rally from April to June, when the stock surged from the mid-$70s to above $90. The RSI is not provided, but the pullback from the June high of $92.73 suggests a cooling of overbought conditions. The 52-week high of $93.22 acts as immediate resistance; a breakout above this level would signal continuation of the uptrend and potentially open the door to analyst high targets. Conversely, the 52-week low of $68.28 provides a support floor, though the current price is well above that level. With a beta of 0.236, Unum is less sensitive to market swings, meaning a breakdown below $87 (recent low) could indicate a shift in sentiment, but the low beta limits downside relative to the market.
Beta
0.24
0.24x market volatility
Max Drawdown
-16.5%
Largest decline past year
52-Week Range
$68-$93
Price range past year
Annual Return
+7.1%
Cumulative gain past year
| Period | UNM Return | S&P 500 |
|---|---|---|
| 1m | -5.4% | +0.6% |
| 3m | +11.6% | +3.4% |
| 6m | +13.6% | +7.1% |
| 1y | +7.1% | +16.4% |
| ytd | +11.9% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNM Fundamental Analysis
Unum's revenue trajectory remains solidly growing, with Q1 2026 revenue of $3.355 billion, up 9.02% year-over-year from $3.0775 billion in Q1 2025. The multi-quarter trend shows consistent expansion, with revenue rising from $3.2025 billion in Q4 2024 to $3.355 billion in Q1 2026. The Unum USA segment, generating $2.066 billion in revenue, is the primary growth driver, while Colonial Life ($520 million) and Unum International ($320 million) contribute meaningfully. This growth trajectory supports the investment case for steady premium expansion and market share retention. Profitability is robust, with Q1 2026 net income of $232 million and a net margin of 6.91%, though this is down from 10.03% in Q2 2025. Gross margin improved to 40.27% in Q1 2026 from 29.59% a year earlier, reflecting better underwriting or mix shift. Operating margin of 9.02% is healthy but below the 12.46% seen in Q2 2025, indicating some margin compression. The company remains profitable with a trailing PE of 18.1x, and the net margin is typical for the life insurance industry. Unum's balance sheet is solid, with a debt-to-equity ratio of 0.35, indicating moderate leverage. Free cash flow (TTM) of $538.8 million is strong, and the company generated $301.2 million in FCF in Q1 2026 alone, easily covering dividends ($78.2 million) and share repurchases ($398.8 million). ROE of 6.64% is reasonable for an insurer, and the FCF yield of approximately 4.0% (FCF/ market cap) suggests healthy cash generation relative to valuation.
Quarterly Revenue
$3.4B
2026-03
Revenue YoY Growth
+9.0%
YoY Comparison
Gross Margin
40.3%
Latest Quarter
Free Cash Flow
$538800000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNM Overvalued?
Since net income is positive ($232 million in Q1 2026), the PE ratio is the primary valuation metric. The trailing PE of 18.1x is elevated relative to the forward PE of 9.2x, implying the market expects significant earnings growth in the coming year. This gap suggests optimism about future profitability, likely driven by margin expansion and buyback accretion. Compared to the industry average (not provided, but life insurers typically trade at 10-15x earnings), Unum's trailing PE of 18.1x appears at a premium. However, the forward PE of 9.2x suggests a discount to the sector, indicating that the market may be pricing in a temporary earnings dip or that the forward estimates are conservative. The PS ratio of 1.02x is low, reflecting the insurance industry's high revenue base relative to market cap. Historically, Unum's trailing PE has ranged from roughly 4x to 19x over the past five years. The current 18.1x is near the top of that range, suggesting the stock is priced for optimistic expectations. The historical low PE of around 4x in 2022 reflected deep value, while the current level implies the market is pricing in sustained earnings growth and successful capital return. The PB ratio of 1.20x is also near the higher end of its historical range (0.44x to 1.30x), reinforcing that valuation is elevated relative to its own history.
PE
18.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Unum's net margin declined from 10.03% in Q2 2025 to 6.91% in Q1 2026, indicating pressure on profitability. Operating margin fell from 12.46% to 9.02% over the same period, driven by rising costs. The debt-to-equity ratio of 0.35 is moderate, but interest expense of $53.1M in Q1 2026 consumes a portion of operating income. Free cash flow of $538.8M TTM is strong, but any sustained margin deterioration could impair the company's ability to maintain its aggressive buyback pace.
Market & Competitive Risks: Unum's trailing P/E of 18.1x is near the high end of its historical range, making it vulnerable to multiple compression if growth disappoints. The stock's beta of 0.236 limits downside but also means it may underperform in strong bull markets. Competitive pressures from other disability insurers and self-insured employer plans could erode market share. Regulatory changes in employee benefits or healthcare could also impact premium growth.
Worst-Case Scenario: A prolonged margin compression combined with a recession-driven spike in disability claims could cause earnings to fall sharply. In this scenario, the stock could decline to its 52-week low of $68.28, representing a -23.3% loss from the current price of $89.05. Historical max drawdown of -16.52% suggests a more moderate downside, but the bear case target of $87 implies a -2.3% decline.
FAQ
The key risks are: (1) Margin compression – operating margin fell from 12.46% in Q2 2025 to 9.02% in Q1 2026, which could persist. (2) Valuation risk – trailing P/E of 18.1x is near historical highs, making the stock vulnerable to multiple compression. (3) Interest rate sensitivity – lower rates could reduce investment income. (4) Competitive pressure – from other insurers and self-insured plans. The most severe risk is a sustained margin decline leading to earnings disappointment and a drop toward the 52-week low of $68.28.
The 12-month forecast is moderately bullish. The base case (55% probability) targets $93-$101, driven by steady revenue growth and buybacks. The bull case (25% probability) targets $101-$123 if margins recover. The bear case (20% probability) targets $68-$87 if margins worsen. The average analyst target is $101.38, implying 13.8% upside. The most likely scenario is the base case, assuming revenue growth of 7-9% and stable margins.
Unum appears undervalued on a forward basis but overvalued on a trailing basis. The forward P/E of 9.2x is a discount to the life insurance sector average of 10-15x and the stock's own trailing P/E of 18.1x. The PS ratio of 1.02x is low, reflecting the industry's high revenue base. Historically, the trailing P/E has ranged from 4x to 19x over five years; the current 18.1x is near the top, suggesting the market is pricing in optimistic earnings growth. The forward P/E implies the market expects significant EPS expansion, likely from buybacks and margin recovery.
Unum is a good buy for investors seeking a defensive value play with income. The forward P/E of 9.2x is attractive relative to the trailing P/E of 18.1x and the life insurance sector average of 10-15x. Analyst consensus is Buy with an average target of $101.38, implying 13.8% upside. However, margin compression and an elevated trailing P/E are risks. For long-term investors with a 3-5 year horizon, the stock offers a compelling risk/reward, but traders should be cautious given the low beta and limited short-term upside.
Unum is best suited for long-term investment due to its low beta (0.236), steady dividend yield (2.29%), and earnings growth driven by buybacks. The stock's low volatility makes it less attractive for short-term trading, as it may not generate quick gains. A minimum holding period of 3-5 years is recommended to allow the buyback program to compound EPS and the forward P/E to converge with fundamentals. Short-term traders may find limited opportunities given the stock's low beta and recent pullback.
